Loading patent…
AssigneeCelera Corporation
InventorsOlga IAKOUBOVA, James J. DEVLIN
Estimating the term…
The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
A method of identifying an individual having an altered risk for developing an acute coronary event or a method of evaluating an individual's likelihood of responding to statin treatment, comprising detecting the presence or absence of one or more alleles of a SNP in said individual's nucleic acids, wherein the SNP is selected from any one of the nucleotide sequences of SEQ ID NOS:121-200 and SEQ ID NOS:251-410, and the presence or absence of the alleles are correlated with an individual's risk for developing an acute coronary event or likelihood of responding to statin treatment.
A method of detecting a single nucleotide polymorphism (SNP) in a nucleic acid molecule, comprising contacting a test sample with a reagent which specifically hybridizes to a SNP in any one of the nucleotide sequences of SEQ ID NOS:1-60 and 121-410 under stringent hybridization conditions, and detecting the formation of a hybridized duplex.
A method of identifying an individual having an altered risk for developing an acute coronary event or a method of evaluating an individual's likelihood of responding to statin treatment, comprising detecting the presence or absence of a polymorphism in said individual's nucleic acids, wherein said polymorphism is in linkage disequilibrium with a SNP in any one of the nucleotide sequences of SEQ ID NOS:121-200 and SEQ ID NOS:251-410, and the presence or absence of the polymorphism is correlated with an individual's risk for developing an acute coronary event or likelihood of responding to statin treatment.
12-27. (canceled)
Dependencies are inferred from the claim text.